Strong Outlook for CRISPR Therapeutics’ Gene Editing Technology, $119 FVE, Shares Undervalued

We assign CRISPR Therapeutics a fair value estimate of $119 per share and view the stock as undervalued, currently trading in 5-star territory. While the company does not yet have approved products, it provides long-term investors with pure play exposure to novel gene editing technology to treat severe, genetic diseases. We assign CRISPR a no-moat rating and positive trend. The company is developing several pipeline candidates spanning a diverse range of diseases with very high unmet needs, which will likely lead to pricing power if its drugs receive approval.